Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Schofield
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.
Requests from sponsors for orphan drug status in the EU are showing a downward trend. It is not yet clear why, but a forthcoming report from the European Commission may provide some answers.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
The annulment of Germany’s ratification of the Unified Patent Court Agreement has dealt the proposed system another serious blow following the UK’s recent decision not to take part because of Brexit.